The therapeutic community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s showing significant promise in clinical trials for managing obesity. Unlike some existing weight loss approaches, retatrutide appears to deliver a significant substantial loss in body mass and benefit metabolic health, particular